Fuan Pharmaceutical Group Co Ltd

Fuan Pharmaceutical Group Co Ltd maintains a relatively strong liquidity position, with a current ratio of 2.32, indicating that it has more than twice the current assets to cover its current liabilities. However, the company's liquidity is assessed as medium risk, and its net cash position is negative after subtracting total debt, suggesting potential short-term financial constraints. The company's debt-to-equity ratio is 0.19, which is relatively low, indicating a conservative capital structure.

In terms of profitability, the company's return on equity (ROE) is 1.76%, and its return on assets (ROA) is 1.34%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's net income of 76,997,130 CNY and operating income of 81,525,490 CNY reflect modest profitability, with a gross profit of 621,738,080 CNY on total revenue of 1,738,291,060 CNY. These figures suggest that the company is generating revenue but is not converting it into high returns relative to its equity or assets.

The company's revenue is primarily concentrated in its domestic operations, with no significant international revenue disclosed. The company operates in a single business segment, which may increase its exposure to local market conditions and regulatory changes. The lack of geographic diversification could pose a risk if the domestic market experiences economic downturns or regulatory shifts.

Looking at the company's growth trajectory, the most recent financial data does not provide a clear indication of future revenue growth. The company's capital expenditure of -108,432,470 CNY suggests that it is not investing heavily in new projects or infrastructure, which may limit its long-term growth potential. The company's free cash flow of 68,239,150 CNY indicates that it has some flexibility to fund operations or return value to shareholders, but the amount is relatively modest given the company's size.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The risk assessment highlights that the company's net cash is negative after subtracting total debt, which could affect its ability to meet short-term obligations. The company's dilution risk is low, and there is no indication of near-term pressure to issue additional shares. The company's conservative capital structure and low debt levels suggest that it is not currently facing significant financial distress.

Recent events and disclosures do not indicate any major changes in the company's operations or financial strategy. The company's latest actual EPS is 0.06 CNY, and its actual revenue is 1,738,291,000 CNY, which aligns with the financial snapshot. There are no recent filings or transcripts that suggest significant operational or strategic shifts.